Project Grant R43AI155046

This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $470,309 in funding to Chromologic LLC, a minority-owned small business in Monrovia, CA, to develop an orally administered probiotic-based treatment for mitigating radiation-induced gastrointestinal and hematopoietic injuries. The project aims to engineer a genetically modified Limosilactobacillus reuteri probiotic strain that...

This U01AI183950 Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,065,656 over 3 years to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate sex-specific differences in intestinal radiosensitivity and mitigation strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research aims to: 1) Examine the role of mitochondrial...

This federal Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) provides $589,425.00 to the Medical College of Wisconsin, Inc. to develop and validate machine learning radiogenomic (ML-RGX) models to predict late toxicity in prostate cancer patients receiving radiation therapy. The grant, awarded on July 1, 2024, aims to: Train ML-RGX models to predict radiation-induced genitourinary (GU) and gastrointestinal (GI) toxicities in...

This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $539,081 to The Leland Stanford Junior University to elucidate sex differences in radiation-induced cardiotoxicity. The project aims to leverage a "cell village" strategy using human induced pluripotent stem cell (iPSC) derivatives from a diverse cohort of 200 individuals. These pooled iPSCs will be differentiated...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $419,133 to the Massachusetts Institute of Technology (MIT) to advance the development of their "AscitesPredict" technology - a zero-passage "ex vivo tumor biosensor" platform that uses single-cell analysis and machine learning to evaluate cell identities and therapeutic sensitivities in patient ascites fluid samples. The key goals of this 3-year...

The National Institute of Environmental Health Sciences (NIEHS) awarded a $238,500 Project Grant under the Environmental Health (CFDA 93.113) federal grant program to the Massachusetts Institute of Technology (MIT) for the project "Leveraging Mutational Analysis of Cell-Free DNA to Identify Carcinogenic Exposure and Enable Early Detection of Cancer". The goal is to develop a novel blood-based analytical tool to rapidly detect mutational profiles of environmental toxicants like...

This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) Federal Grant Program provides $900,804 to Lena Biosciences, Inc., a woman-owned small business, to develop an integrated microphysiological screening platform with "virtual human" models for assessing chemical toxicity. The key products and services to be delivered include: A 96-well microphysiological screening platform that combines elements of...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $596,095 to the University of Washington to develop and validate a personalized, patient-friendly radiation tracking device for 177Lu-DOTATATE theranostic treatments. The "Personalized Remote Radiation Tracking Portable Organ Dosimetry Device" (PRRT PODD) will enable real-time monitoring of radiation dose to patients' organs and tumors, allowing for personalization...

This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $644,622 to the Regents of the University of Michigan to develop tools and predictive models for dosimetry-guided radioligand therapy (RLT) for metastatic castrate-resistant prostate cancer (mCRPC). The key objectives are: 1) developing a novel method for bone marrow dosimetry, 2) building models to predict absorbed dose from pre-therapy PET imaging and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,829 to the University of Washington to develop a generalizable framework for guiding re-irradiation treatment. The key objectives of the project are: Quantifying the evolution of normal tissue damage and recovery after radiation therapy using imaging biomarkers for liver and lung injury. The goal is to parameterize the dose-dependent recovery from radiation-induced...